Post hoc analysis of 336 children aged 6–11 with type 2 asthma in VOYAGE: dupilumab vs placebo cut severe exacerbations by 45% (non-significant), 75% and 60% in non-, mono- and multi-allergen-sensitised subgroups, with no significant interaction by sensitisation.
Secondary analysisn = 336
Phipatanakul et al. Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level